Calendar

August 2016
SunMonTueWedThuFriSat
 << < > >>
 123456
78910111213
14151617181920
21222324252627
28293031   

biology

biology and science

Who's Online?

Member: 0
Visitor: 1

Announce

rss Syndication

Categories

Choose a skin



14 Sep 2012 

DN is the first cause leading to the North American end-stage renal disease (ESRD)tnf alpha


DN is the first cause leading to the North American end-stage renal
disease (ESRD), while the 2011 Shanghai dialysis registration information DN
accounted for 13.5%, ranking second in the treatment of DN is still the lack of
effective drug treatment in addition to hypoglycemiclowering blood pressure as
well as blocking the RAAS system and treatment of complications, no effective
therapy clinical findings, even if good control of blood glucose blood
pressure, kidney damage still can not be completely prevented DN pathogenesis,
and currently that is closely related to a variety of factors,protein kinase C
pathway glycosylation terminal metabolite pathways including polyol pathway and
oxidative stress approach, we found that the DM group and DN group of patients
with CRP IL-6 TNF-water were significantly higher than the healthy group, DN
groupCRP IL-6TNF-levels are significantly higher than those in the DM group,
suggesting that patients with DN in addition to abnormal glucose metabolism and
lipid metabolism and hemodynamic abnormalities, there are still
micro-inflammatory state, consistent with the relevant study IL-6 TNF-from
macrophages fator endothelial cells, are multifunctional proinflammatory
cytokines, involved in the immune response and inflammation IL-6 is a variety
of cells in vivo with a wide range of biological activity of the cytokine IL-6
release can weaken the function of the islet cellscause insulin resistance
insulin secretory dysfunction and metabolic syndrome, leading to the
development of diabetes and diabetic nephropathy


Admin · 293 views · 0 comments
Categories: First category
06 Sep 2012 

Of rheumatoid arthritis patients with tumor necrosis factor inhibitors status of investigation


Understanding of rheumatoid arthritis (rheumatoid arthritis, RA)
patients with tumor necrosis factor (tumor necrosis factor, TNF) inhibitors
status quo as well as the factors that affect its application. Methods: A
multi-center Situation Questionnaire survey method to record the selected
general and TNF inhibitors, calculate the cost of patients with TNF inhibitors,
analysis of TNF inhibitors application status and impact of the application of
the relevant factor. Results: July 2009 to November 2010, a total of 21 major
hospitals nationwide rheumatoid immune outpatients of 095 RA patients completed
questionnaires, of which 112 patients TNF inhibitor (infliximab, trade name
class grams or etanercept, trade name benefits Saipu) treatment, the total
study population 10. 2% (etanercept 81 cases, accounting for 7.4%; class grams
of 26 cases, accounting for 2.4%; Both formulations are used in 5 cases,
accounting for 0.5%). Application class g treatment <3 months 3 to 6 months
who are 38. 1%, etanercept treatment <3 months 3 to 6 months, respectively
accounting for 38. 5% and 25. 0%. Application infliximab treatment <3
months, 3 to 6 months and 6 to 9 months by the Health Assessment Questionnaire
(health assessment question-naire, HAQ) scores were 1. 1,0. 5,0. 1, the
corresponding score of etanercept. 3,1. 0,0. 3. Application infliximab treatment
<3 months, 3 to 6 months and 6 to 9 months expenses were 24,525. 0,69 300.
0,96 800. $ 0, the cost of etanercept 7394. 8,9 158. 6,54 910. $ 9. Application
infliximab treatment <3 months, 3 to 6 months and 6 to 9 months in patients
with indirect economic losses were 365. 6,0,158. $ 9, etanercept 2158. 4,288.
5,180. $ 1. Proportion of Allergy and Infectious application etanercept are 3.
5% are in the application class grams. 5%. Logistic regression analysis showed
that the level of education affect the TNF inhibitors applications related
factors. Conclusion: in our large hospitals for treatment of RA patients, about
10% of the applied TNF inhibitors, their condition with the application of a
TNF inhibitor treatment extended mitigated, to extend and increase the total
cost of treatment with the medication regimen, but the indirect economic losses
with treatment prolonged decrease in major adverse reaction to allergies and
infections, the level of education is mainly related factors affect its
application.


Admin · 377 views · 0 comments
Categories: First category
31 Aug 2012 

DN is the first cause leading to the North American end-stage renal disease

DN is the first cause leading to the North American end-stage renal disease (ESRD), while the 2011 Shanghai dialysis registration information DN accounted for 13.5%, ranking second in the treatment of DN is still the lack of effective drug treatment in addition to hypoglycemiclowering blood pressure as well as blocking the RAAS system and treatment of complications, no effective therapy clinical findings, even if good control of blood glucose blood pressure, kidney damage still can not be completely prevented DN pathogenesis, and currently that is closely related to a variety of factors,protein kinase C pathway glycosylation terminal metabolite pathways including polyol pathway and oxidative stress approach, we found that the DM group and DN group of patients with CRP IL-6 TNF-water were significantly higher than the healthy group, DN groupCRP IL-6TNF-levels are significantly higher than those in the DM group, suggesting that patients with DN in addition to abnormal glucose metabolism and lipid metabolism and hemodynamic abnormalities, surviving in the micro-inflammatory state, consistent with relevant research
Admin · 259 views · 0 comments
Categories: First category
28 Aug 2012 

tumor necrosis factor (TNF-) levels of CRPusing the Beckman-delta4automatic biochemical analyzer


Methods of observation randomly selected from May 2007 to March
2011, the outpatient and inpatient DN patients DM patients 30 cases each, and
the other to extract the 2009 hospital examination center 30 healthy patients
and excluded the following circumstances: (1) recent (time of onset<2 weeks)
acute complications of diabetes (such as: ketoacidosis, hyperosmolar coma
lactic acidosis, etc.)-infected patients (2) severe metabolic disorders and
merger nearly a month trauma surgery (3)biochemical room of our hospital acute
state of emergency, the combined impact of chronic diarrhea, heart failure
proteinuria observed by each group of C-reactive protein (CRP), interleukin-6
(IL-6) tumor necrosis factor (TNF-) levels of CRP using the
Beckman-delta4automatic biochemical analyzer; IL-6TNF-measured by
radioimmunoassay kit was purchased from Poole Albert biological Technology Co.,
Ltd. (batch number: 20090227), and in strict accordance with the instructions



Statistical methods using SPSS 11.5 statistical software for
statistical processing, the detection data (XS), measurement data using paired
and group t test P <0.05 for the difference was statistically significant


Admin · 255 views · 0 comments
Categories: First category
23 Aug 2012 

The article discusses the olmesartan serum TNF-α and adiponectin on insulin resistance


The article
discusses the olmesartan serum TNF-
α and adiponectin on insulin resistance. Normal 39 male
Sprague-Dawley rats were randomly divided into normal control group (n = 9) and
model group (n = 30). Tail vein blood check after 6 weeks of high fat diet and
fasting blood glucose (FBG), fasting insulin (FINS), and insulin sensitivity
index (ISI) to determine the 27 rats with insulin resistance model.
Insulin-resistant rats were randomly divided into three groups: (1) model group
(n = 9): given the high-fat diet; the
metformin group (n = 9): on the basis of the high-fat diet plus
metformin (300 mg
kg- 1 d-1); the olmesartan group (n = 9): on the basis of the high-fat diet with
olmesartan (3mg kg-1
d-1). Six
weeks after the intervention, the determination of FBG, FINS, the calculation
of the ISI; determination of TNF-
α and adiponectin levels. The results of the olmesartan group and
model group, TNF-
α was
significantly reduced (P <0.01), adiponectin was significantly higher (P
<0.05). Conclusion olmesartan may be by reducing TNF-
α, increased adiponectin levels and improve insulin resistance.



Insulin resistance is not only one of the root causes of type 2
diabetes, it is associated with hypertension, high cholesterol, high blood
viscosity, lipid metabolism related to the pathological basis of
atherosclerosis. But the mechanism of insulin resistance is very complex in
recent years, studies have shown that the two fat cytokines tumor necrosis factor-
α (TNF-alpha) and adiponectin can influence insulin sensitivity.
Adiponectin can improve insulin sensitivity, fat-derived inflammatory factors
TNF-
α can reduce the
target tissue sensitivity to insulin, both closely related to insulin
resistance. Meanwhile, studies have shown that ARB may improve insulin
resistance. However, the mechanism of action of improving insulin resistance is
not very clear. In this study, a new angiotensin II receptor antagonist (ARB),
Ogilvy & Mather losartan intervention in insulin r
esistant rats to observe the animal after administration of insulin
sensitivity and TNF-
α and adiponectin factors.


Admin · 2933 views · 0 comments
Categories: First category

1, 2  Next page